Search Results
May 13, 2026, 12:16 ET Non-Animal Alternative Testing Market Size to Reach $29.4 Billion by 2030, Globally, at 13.5% CAGR: Allied Market Research
introduced in August 2024. Japan has a long history of both Kampo and precision medicine, and also is investing in research on alternative testing through AMED and other national research organizations. LAMEA (Emerging Opportunity Region): Consists of Latin America, Middle East and Africa also developing
More news about: Allied Market Research
Apr 02, 2026, 06:00 ET AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies
cost of goods."The AVC-203 program is supported by a grant of up to $40 million from the Japan Agency for Medical Research and Development ("AMED") (Project Name: "Strengthening Program for Pharmaceutical Startup Ecosystem" R&D Project Title: "Clinical development of bispecific allogeneic
More news about: AvenCell Therapeutics, Inc.
Mar 24, 2026, 07:55 ET EpiFrontier Therapeutics Secures up to $32M Grant from the Japan Agency for Medical Research and Development to Advance Novel Therapy for Beta Globin Disorders
www.epifrontiertx.com]About AMEDThe Japan Agency for Medical Research and Development (AMED), established in 2015, is a government agency dedicated to accelerating medical innovation and strengthening Japan's global competitiveness in healthcare. AMED supports integrated research and
More news about: EpiFrontier Therapeutics
Feb 25, 2026, 01:24 ET Kanazawa University research: Wnt signaling drives stomach cancer spread by reshaping surrounding tissue
(WPI) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, and by the Japan Agency for Medical Research and Development (AMED) (24ama22152h0002 to H.O.). Contact Kimie Nishimura (Ms)Project Planning
More news about: Kanazawa University
Jan 07, 2026, 07:33 ET Rakuten Medical Raises $100 Million in Oversubscribed Series F to Accelerate Development Toward U.S. Regulatory Approval
RM-0256 photoimmunotherapy in Japan in Q2 2026, supported by AMED1 grant funding.Esophageal and gynecologic cancers: Support two ongoing IITs of ASP-1929 photoimmunotherapy in Japan; the gynecologic cancer IIT is supported by AMED funding.Pancreatic and non-small cell lung cancers:
More news about: Rakuten Medical, Inc.
Dec 18, 2025, 21:59 ET Kanazawa University research: a new strategy for immune tolerance
Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED) (No. 24ck0106967h0001 to TY). Science and Technology Platform for Advanced Biological Medicine from AMED (No. 22am0401019h0004 to RH). Contact:Kimie Nishimura
More news about: Kanazawa University
Dec 07, 2025, 20:00 ET Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others
diseases. The GHIT Fund is the second organization from Japan to join GloPID-R as a member after the Japan Agency for Medical Research and Development (AMED). We will continue to support the development of innovative diagnostic technologies to enable swift responses to future public health challenges.1
More news about: GHIT Fund
Dec 07, 2025, 20:00 ET Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others
diseases. The GHIT Fund is the second organization from Japan to join GloPID-R as a member after the Japan Agency for Medical Research and Development (AMED). We will continue to support the development of innovative diagnostic technologies to enable swift responses to future public health challenges.1
More news about: GHIT Fund
Nov 18, 2025, 09:00 ET New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
Partnerships for Innovative Research Ecosystem (ASPIRE) program, a bilateral initiative between Japan's Agency for Medical Research and Development (AMED) and Australia's National Health and Medical Research Council (NHMRC). The ASTRA Consortium will formally launch at the inaugural ASTRA Conference,
More news about: 10x Genomics, Inc.
Nov 07, 2025, 08:00 ET Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors
1010. Dr. Fischer joins the board following a strong Series A financing and a $71M non-dilutive grant from the Japanese Government's AMED program. These company milestones position Shinobi to continue development of NJA-001, an iPS-T cell therapy targeting GPC3 for solid tumors, and NJA-201,
More news about: Shinobi Therapeutics
Nov 06, 2025, 02:11 ET Kanazawa University research: Protein droplets in the nucleus guard against cancer
Agency for Medical Research and Development (AMED) (JP22gm6310008) to M.N., Yasuda Medical Foundation to M.N., Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED, and the World Premier International Research
More news about: Kanazawa University
Oct 07, 2025, 09:00 ET Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
financing round, raising JPY 1.055 billion (USD 7.2 million) from venture capital firms and the Japan Agency for Medical Research and Development (AMED). Including grants and subsidies, Celaid's cumulative funding has reached JPY 2.52 billion (USD 17.14 million). This financing
More news about: Celaid Therapeutics Inc.
Aug 14, 2025, 18:08 ET Twilio Set to Join S&P MidCap 400
Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE: TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100
More news about: S&P Dow Jones Indices
Jun 30, 2025, 14:52 ET AvenCell erhält bis zu 40 Mio. USD AMED-Förderung zur Weiterentwicklung des allogenen CAR-T-Programms
hämatologische Krebserkrankungen und Autoimmunerkrankungen entwickelt, gab heute bekannt, dass es von der Japan Agency for Medical Research and Development (AMED) eine Förderung in Höhe von bis zu 40 Mio. USD erhalten hat. Diese nicht verwässernde Förderung wird die weltweite Entwicklung des AVC203-Kandidaten
More news about: AvenCell Therapeutics, Inc.
Jun 30, 2025, 10:06 ET AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
announced it has been awarded a grant of up to $40 million from the Japan Agency for Medical Research and Development (AMED). This non-dilutive funding will support the worldwide development of AvenCell's AVC203 candidate – an IND-stage, dual-antigen (CD19 & CD20) allogeneic
More news about: AvenCell Therapeutics, Inc.